Arvinas reported Q2 2026 results, marking a closely watched update for investors assessing whether the biotech is nearing a financial turning point. Focus now s

Arvinas reported Q2 2026 results, marking a closely watched update for investors assessing whether the biotech is nearing a financial turning point. Focus now shifts to management’s outlook and how ongoing Alzheimer’s and oncology R&D supports the path ahead.